Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme

@article{Sotelo2006AddingCT,
  title={Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme},
  author={Julio Sotelo and Eduardo Briceo and M. M. C. Lpez-Gonzlez},
  journal={Annals of Internal Medicine},
  year={2006},
  volume={144},
  pages={337-343}
}
Context The median survival for patients with glioblastoma multiforme is 1 year despite aggressive treatment. Chloroquine interferes with cellular mechanisms that might cause treatment resistance. Content In this single-center, randomized, double-blind, placebo-controlled trial, 30 patients receiving surgery, chemotherapy, and radiotherapy for glioblastoma multiforme were randomly assigned to receive chloroquine or placebo for 12 months. Median survival was 24 months for patients who received… 
Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme.
Chloroquine in glioblastoma—New horizons for an old drug
TLDR
There has been some improvement in the survival of patients with GBM with the use of temozolamide along with postoperative radiotherapy, and one of the important mechanisms of benefit from using radiotherapy and temzolamide is the radiopotentiation produced by temozoamide.
The effect of chloroquine treatment in malignant astrocytomas on prognosis
TLDR
The chloroquine treatment was not been found to be effective for the medical treatment of MAs.
Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial
TLDR
WBRT with concurrent, short-course CQ is well-tolerated in patients with brain metastases and a trend toward increased overall survival was observed in Patients with wild-type IDO2 compared to patients with heterozygous or homozygous configurations that ablate IDO1 enzyme activity.
Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial
TLDR
A daily dose of 200 mg chloroquine was determined to be the maximum tolerated dose when combined with radiotherapy and concurrent temozolomide for newly diagnosed glioblastoma.
Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial
TLDR
Hydxychloroquine with short-course radiotherapy did not improve survival compared to radiotherapy alone in elderly patients with glioblastoma and the outcome in the control arm was better than expected and the excess of deaths in the hydroxy chloroquine group appeared unrelated to cancer.
Drug repurposing for the treatment of glioblastoma multiforme
TLDR
The spiraling costs of new antineoplastic drugs and the long time required for them to reach the market demands a profoundly different approach to keep lifesaving therapies affordable for cancer patients and repurposing can represent a relatively inexpensive, safe and fast approach to glioblastoma treatment.
FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma
TLDR
This case series treated five patients with histologically confirmed rGBM with re-RT and 250 mg CQ daily and observed encouraging responses to CQ and re- RT, and plans to conduct a CQ dose escalation study combined withRe-RT.
Sirolimus and Hydroxychloroquine as an Add-On to Standard Therapy for Glioblastoma Multiforme: Case Report
TLDR
An advanced targeting strategy is an urgent prerequisite for GBM treatment and the addition of bevacizumab to standard RT-TMZ therapy did not significantly improve the overall survival duration.
Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer
TLDR
The addition of chloroquine to gemcitabine was well tolerated and showed promising effects on the clinical response to the anti-cancer chemotherapy.
...
...

References

SHOWING 1-10 OF 65 REFERENCES
Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine.
TLDR
Chronic administration of chloroquine greatly enhanced the response of GBM to antineoplastic treatment, and these favorable results appear mediated by its strong antimutagenic effect that precludes the appearance of resistant clones during radiotherapy and chemotherapy.
Current management of glioblastoma multiforme.
TLDR
Translational research efforts should pursue a broad research agenda until productive avenues are identified to quantify the delivery of novel agents to the malignant brain tumor cells and determine the maximum tolerated dose (MTD) and preliminary efficacy data on novel agents before initiating combination therapies.
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
TLDR
It is suggested that it is best to use radiotherapy in the post-surgical treatment of malignant glioma and to continue the search for an effective chemotherapeutic regimen to use in addition to radiotherapy.
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
TLDR
This study confirms that local chemotherapy with BCNU wafers is well tolerated and offers a survival benefit to patients with newly diagnosed malignant glioma.
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
  • R. Stupp, P. Dietrich, S. Leyvraz
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma.
Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.
TLDR
Carmustine applied locally in a biodegradable polymer at the time of primary operation, seems to have a favorable effect on the life span of patients with high-grade gliomas.
Neuro-oncology clinical trials: promise and pitfalls.
  • M. Gilbert
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2001
TLDR
Three manuscripts in this journal describe studies using the chemotherapy agent, temozolomide, for recurrent malignant gliomas and recurrent brain metastases, and the findings are not directly comparable to other phase II studies.
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
TLDR
An analysis of prognostic factors indicates that the initial performance status, age, the use of only a surgical biopsy, parietal location, the presence of seizures, or the involvement of cranial nerves II, III, IV, and VI are all of significance.
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.
TLDR
Gross-total tumor resection is associated with longer survival in patients with GBM, especially when other predictive variables are favorable.
...
...